...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021).
【24h】

A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021).

机译：食管癌顺铂/ 5-FU同步放化疗的II期随机研究：短期输注与长期输注化疗（KROSG0101 / JROSG021）。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: A randomized phase II study was conducted to compare the toxicity and efficacy of combining short-term chemotherapy (CT) or protracted CT with radiotherapy (RT) for esophageal cancer. MATERIALS AND METHODS: Eligible patients were <75 years and with performance status (PS) of 0-2, and had stages II-IVA esophageal cancer. Two cycles of cisplatin 70 mg/m(2) for 1 day and 5FU 700 mg/m(2) for 5 days (arm A) or cisplatin 7 mg/m(2) for 10 days and 5FU 250 mg/m(2) for 14 days (arm B) were given with RT of 60Gy/30 fractions/7 weeks (1-week split). RESULTS: Of 91 patients enrolled, 46 were randomized to arm A and 45 to arm B. Two cycles of CT were given concurrently with RT for 89% in arm A and for 71% in arm B with significant difference (P=.031). The 2- and 5-year overall survival rates for arm A were 46% and 35%, while those for arm B were 44% and 24%, respectively, without significant difference. The 2- and 5-year progression-free survival rates for arm A were 30% and 30%, while those for arm B were 29% and 12%, respectively. CONCLUSIONS: Protracted infusion CT with RT provides no advantage over standard short-term infusion CT with RT for esophageal cancer.
机译：目的：进行了一项随机的II期研究，以比较短期化疗（CT）或长期CT与放疗（RT）联合治疗食管癌的毒性和疗效。材料与方法：符合条件的患者<75岁，表现状态（PS）为0-2，患有II-IVA期食管癌。两个周期的顺铂70 mg / m（2）1天和5FU 700 mg / m（2）5天（A组）或顺铂7 mg / m（2）10天和5FU 250 mg / m（2） ）连续14天（B组），RT为60Gy / 30分数/ 7周（1周分割）。结果：在入组的91例患者中，有46例被随机分配到A臂，45例被随机分配到B臂。A臂89％的患者和B臂71％的患者在放疗的同时行两个周期的CT检查（P = .031） 。 A组的2年和5年总生存率分别为46％和35％，而B组的分别为44％和24％，无显着差异。 A组的2年和5年无进展生存率分别为30％和30％，而B组的分别为29％和12％。结论：对于食管癌，采用RT进行长期输注CT优于采用RT进行标准短期输注CT的优势。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号